{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T02:37:02Z","timestamp":1786847822489,"version":"build-2736575974"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.biopha.2017.01.116","type":"journal-article","created":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T16:01:01Z","timestamp":1485878461000},"page":"745-753","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["URB597 reduces biochemical, behavioral and morphological alterations in two neurotoxic models in rats"],"prefix":"10.1016","volume":"88","author":[{"given":"Marisol","family":"Maya-L\u00f3pez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hipolito A.","family":"Ruiz-Contreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"de Jes\u00fas Negrete-Ru\u00edz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juli\u00e1n El\u00edas","family":"Mart\u00ednez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Ben\u00edtez-Valenzuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Laura","family":"Col\u00edn-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juana","family":"Villeda-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"S\u00e1nchez-Chapul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Parra-Cid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Rangel-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abel","family":"Santamar\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2017.01.116_bib0005","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1476-5381.2008.00088.x","article-title":"The endocannabinoid system as a target for the treatment of motor dysfunction","volume":"156","author":"Fernandez-Ruiz","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2017.01.116_bib0010","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1385\/NMM:7:1-2:037","article-title":"Cannabinoid receptors and their role in neuroprotection","volume":"7","author":"van der Stelt","year":"2005","journal-title":"Neuromol. Med."},{"key":"10.1016\/j.biopha.2017.01.116_bib0015","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jns.2012.06.004","article-title":"Mitochondrial disturbances, excitotoxicity, neuroinflammation and kynurenines: novel therapeutic strategies for neurodegenerative disorders","volume":"322","author":"Z\u00e1dori","year":"2012","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.biopha.2017.01.116_bib0020","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2826.2008.01671.x","article-title":"Cannabinoid receptors: where they are and what they do","volume":"20","author":"Mackie","year":"2008","journal-title":"J. Neuroendocrinol."},{"key":"10.1016\/j.biopha.2017.01.116_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2010.02.013","article-title":"Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities","volume":"80","author":"Bosier","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2017.01.116_bib0030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1527-3458.2006.00021.x","article-title":"Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597)","volume":"12","author":"Piomelli","year":"2006","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.biopha.2017.01.116_bib0035","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1476-5381.2012.02208.x","article-title":"The FAAH inhibitor URB597 efficiently reduces tyrosine hydroxylase expression through CB1- and FAAH-independent mechanisms","volume":"169","author":"Bosier","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2017.01.116_bib0040","doi-asserted-by":"crossref","first-page":"878","DOI":"10.3390\/molecules15020878","article-title":"3-Nitropropionic acid as a tool to study the mechanisms involved in Huntington\u2019s disease: past, present and future","volume":"15","author":"T\u00fanez","year":"2010","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2017.01.116_bib0045","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.neuro.2014.10.004","article-title":"Potential of protease inhibitor in 3-nitropropionic acid induced Huntington\u2019s disease like symptoms: mitochondrial dysfunction and neurodegeneration","volume":"45","author":"Hariharan","year":"2014","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.biopha.2017.01.116_bib0050","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/j.1471-4159.2005.03515.x","article-title":"3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington\u2019s disease","volume":"95","author":"Brouillet","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.biopha.2017.01.116_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.freeradbiomed.2013.03.018","article-title":"Mitochondrial disease of the brain","volume":"63","author":"Chaturvedi","year":"2013","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.biopha.2017.01.116_bib0060","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.mito.2015.10.007","article-title":"Differences in mitochondrial function in homogenated samples from healthy and epileptic specific brain tissues revealed by high-resolution respirometry","volume":"25","author":"Burtscher","year":"2015","journal-title":"Mitochondrion"},{"key":"10.1016\/j.biopha.2017.01.116_bib0065","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ntt.2014.03.005","article-title":"An enteric nervous system progenitor cell implant promotes a behavioral and neurochemical improvement in rats with a 6-OHDA-induced lesion","volume":"43","author":"Parra-Cid","year":"2014","journal-title":"Neurotoxicol. Teratol."},{"key":"10.1016\/j.biopha.2017.01.116_bib0070","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0301-0082(01)00003-X","article-title":"Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine, and MPTP: contribution to the apoptotic theory in Parkinson\u2019s disease","volume":"65","author":"Blum","year":"2001","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.biopha.2017.01.116_bib0075","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.expneurol.2013.01.024","article-title":"Modeling dyskinesia in animal models of Parkinson disease","volume":"256","author":"Morin","year":"2014","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.biopha.2017.01.116_bib0080","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00213-006-0589-7","article-title":"Effects of the FAAH inhibitor, URB597, and anandamide on lithium-induced taste reactivity responses: a measure of nausea in the rat","volume":"190","author":"Cross-Mellor","year":"2007","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.biopha.2017.01.116_bib0085","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"1998"},{"key":"10.1016\/j.biopha.2017.01.116_bib0090","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.neuroscience.2014.11.016","article-title":"Cannabinoid receptor agonists reduce the short-term mitochondrial dysfunction and oxidative stress linked to excitotoxicity in the rat brain","volume":"285","author":"Rangel-L\u00f3pez","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.biopha.2017.01.116_bib0095","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the Folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J. Biol. Chem"},{"key":"10.1016\/j.biopha.2017.01.116_bib0100","first-page":"51785","article-title":"Behavioral and locomotor measurements using an open field activity monitoring system for skeletal muscle diseases","volume":"91","author":"Tatem","year":"2014","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.biopha.2017.01.116_bib0105","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/j.1471-4159.2007.05174.x","article-title":"Excitotoxic damage, disrupted energy metabolism, and oxidative stress in the rat brain: antioxidant and neuroprotective effects of l-carnitine","volume":"105","author":"Silva-Adaya","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.biopha.2017.01.116_bib0110","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3389\/fphar.2013.00169","article-title":"The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia","volume":"4","author":"S\u00e1nchez-Bl\u00e1zquez","year":"2014","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2017.01.116_bib0115","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s002210050016","article-title":"Effects of systemic 3-nitropropionic acid-induced lesions of the dorsal striatum on cannabinoid and mu-opioid receptor binding in the basal ganglia","volume":"130","author":"Page","year":"2000","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.biopha.2017.01.116_bib0120","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1097\/00001756-200107200-00017","article-title":"Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington\u2019s disease","volume":"12","author":"Lastres-Becker","year":"2001","journal-title":"NeuroReport"},{"key":"10.1016\/j.biopha.2017.01.116_bib0125","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/syn.10054","article-title":"Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington\u2019s disease","volume":"44","author":"Lastres-Becker","year":"2002","journal-title":"Synapse"},{"key":"10.1016\/j.biopha.2017.01.116_bib0130","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1006\/exnr.1998.6848","article-title":"Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat","volume":"152","author":"Kirik","year":"1998","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.biopha.2017.01.116_bib0135","doi-asserted-by":"crossref","first-page":"11047","DOI":"10.1073\/pnas.191353298","article-title":"Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter","volume":"98","author":"Gainetdinov","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.biopha.2017.01.116_bib0140","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1111\/j.1471-4159.1992.tb10990.x","article-title":"Reactive oxygen species and the central nervous system","volume":"59","author":"Halliwell","year":"1992","journal-title":"J. Neurochem."},{"key":"10.1016\/j.biopha.2017.01.116_bib0145","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/1742-2094-8-129","article-title":"Generation of reactive oxygen species in 1-methyl-4-phenylpyridinium (MPP+) treated dopaminergic neurons occurs as an NADPH oxidase-dependent two-wave cascade","volume":"8","author":"Zawada","year":"2011","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.biopha.2017.01.116_bib0150","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10517-016-3377-3","article-title":"Differences in monoamine oxidase activity in the brain of Wistar and August rats with high and low locomotor activity: a cytochemical study","volume":"161","author":"Sergutina","year":"2016","journal-title":"Bull. Exp. Biol. Med."},{"key":"10.1016\/j.biopha.2017.01.116_bib0155","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.expneurol.2007.07.021","article-title":"Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson\u2019s disease: role of CB(1) and TRPV1 receptors","volume":"208","author":"Morgese","year":"2007","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.biopha.2017.01.116_bib0160","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.nbd.2014.11.024","article-title":"Activation of PPAR\u03b3 receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats","volume":"74","author":"Martinez","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.biopha.2017.01.116_bib0165","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.neulet.2016.04.068","article-title":"URB597 inhibits oxidative stress induced by alcohol binging in the prefrontal cortex of adolescent rats","volume":"624","author":"Peli\u00e7\u00e3o","year":"2016","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.biopha.2017.01.116_bib0170","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.bbr.2016.07.009","article-title":"Cannabinoid receptor agonist WIN55,212-2 and fatty acid amide hydrolase inhibitor URB597 may protect against cognitive impairment in rats of chronic cerebral hypoperfusion via PI3K\/AKT signaling","volume":"313","author":"Su","year":"2016","journal-title":"Behav. Brain. Res."},{"key":"10.1016\/j.biopha.2017.01.116_bib0175","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1002\/ana.10483","article-title":"Oxidative stress in Parkinson\u2019s disease","volume":"53","author":"Jenner","year":"2003","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.biopha.2017.01.116_bib0180","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bbadis.2009.09.013","article-title":"Abnormal mitochondrial dynamics and neurodegenerative diseases","volume":"1802","author":"Su","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.biopha.2017.01.116_bib0185","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1016\/j.neuropharm.2012.02.003","article-title":"Differential modulations of striatal tyrosine hydroxylase and dopamine metabolism by cannabinoid agonists as evidence for functional selectivity in vivo","volume":"62","author":"Bosier","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopha.2017.01.116_bib0190","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/imm.12233","article-title":"Inflammation in neurodegenerative diseases\u2014an update","volume":"142","author":"Amor","year":"2014","journal-title":"Immunology"},{"key":"10.1016\/j.biopha.2017.01.116_bib0195","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1124\/jpet.104.078980","article-title":"Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3\u2032-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoyl ethanolamide deactivation","volume":"313","author":"Fegley","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2017.01.116_bib0200","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00213-008-1104-0","article-title":"Increase of brain endocannabinoid anandamide levels by FAAH inhibition and alcohol abuse behaviours in the rat","volume":"198","author":"Cippitelli","year":"2008","journal-title":"Psychopharmacology (Berl.)"},{"issue":"Suppl. S2","key":"10.1016\/j.biopha.2017.01.116_bib0205","first-page":"A15","article-title":"FAAH inhibition is protective in a cell culture model of Parkinson\u2019s disease","volume":"88","author":"Zeissler","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.biopha.2017.01.116_bib0210","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13024-015-0012-0","article-title":"Promising cannabinoid-based therapies for Parkinson\u2019s disease: motor symptoms to neuroprotection","volume":"10","author":"More","year":"2015","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.biopha.2017.01.116_bib0215","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbi.2016.06.010","article-title":"Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson\u2019s disease","volume":"57","author":"Celorrio","year":"2016","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.biopha.2017.01.116_bib0220","doi-asserted-by":"crossref","DOI":"10.1007\/s12640-016-9698-1","article-title":"URB597 and the cannabinoid WIN55,212-2 reduce behavioral and neurochemical deficits induced by MPTP in mice: possible role of redox modulation and NMDA receptors","author":"Escamilla-Ram\u00edrez","year":"2017","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.biopha.2017.01.116_bib0225","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1476-5381.2012.02208.x","article-title":"The FAAH inhibitor URB597 efficiently reduces tyrosine hydroxylase expression through CB1- and FAAH-independent mechanisms","volume":"169","author":"Bosier","year":"2013","journal-title":"Br. J. Pharmacol."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332216323368?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332216323368?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T12:07:43Z","timestamp":1778242063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332216323368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":45,"alternative-id":["S0753332216323368"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2017.01.116","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"URB597 reduces biochemical, behavioral and morphological alterations in two neurotoxic models in rats","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2017.01.116","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}